Open-Angle Glaucoma Therapeutics Market to Record a CAGR of 7.18%, Development of Biologics to be a Key Trend – Technavio


NEW YORK, Sept. 27, 2022 /PRNewswire/ — One of the key trends in the open-angle glaucoma therapeutics market is the development of biologics. The market landscape largely contains small molecules, including PGAs and non-PGAs. These molecules are the main option for the treatment of open-angle glaucoma. However, side effects such as lack of patient adherence and the high cost of drugs have resulted in unmet medical needs for effective novel treatments. Several biologics offer better safety and efficacy over small molecules. Thus, the development of new biologics is expected to address the unmet needs for safe and novel treatment of open-angle glaucoma. This, in turn, will boost the growth of the market during the forecast period.

The open-angle glaucoma therapeutics market size is expected to grow by USD 2.58 billion from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 7.18% during the forecast period, according to Technavio. The promising pipeline and recent approvals are driving the open-angle glaucoma therapeutics market growth. However, factors such as advances in glaucoma surgeries may challenge the market growth.

Get a comprehensive report summary that describes the market size and forecast along with research methodology. The FREE sample report is available in PDF format

Open-Angle Glaucoma Therapeutics Market: Product Landscape

By product, the market has been segmented into PGAs and non-PGAs. The PGAs segment will be the largest contributor to market growth during the forecast period. PGAs are the first-line treatment for open-angle glaucoma. Currently, Bimatoprost, latanoprost, and travoprost are the available PGAs in the market, which are approved for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Such factors will boost the market growth during the forecasted period.

Open-Angle Glaucoma Therapeutics Market: Geographic Landscape

By geography, the market has been segmented into North America, Europe, APAC, and Rest of World (ROW). North America is going to have lucrative growth during the forecast period. About 51% of the market’s overall growth is expected to originate from the region. The US and Canada are the key countries in the open-angle glaucoma therapeutics market in North America.

Open-Angle Glaucoma Therapeutics Market: Key Companies and their Offerings

AbbVie Inc., Aerie Pharmaceuticals Inc, Alcon Inc., Bausch Health Co Inc, D.Western, Therapeutics Institute Inc, Hikma Pharmaceuticals Plc, Laboratories Sophia, Merck and Co. Inc., Nicox SA, Novartis AG, Ocuphire Pharma Inc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., PharmaMar SA, Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd, Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., among others, are the main players in the market. The key offerings of some of these vendors are listed below:

  • AbbVie Inc. – The company offers open-angle glaucoma therapeutics such as Lumigan and Combigan.
  • Aerie Pharmaceuticals Inc – The company offers open-angle glaucoma therapeutics, namely Rocklatan and Rhopressa.
  • Alcon Inc. – The company offers open-angle glaucoma therapeutics, namely Travatan.
  • Bausch Health Co Inc – The company offers open-angle glaucoma therapeutics, namely Vyzulta.
  • Hikma Pharmaceuticals Plc – The company offers open-angle glaucoma therapeutics, namely Diazepam.

This report provides a full list of key vendors, their strategies, and the latest developments. Request a FREE PDF Sample Now

Open-Angle Glaucoma Therapeutics Market: What Our Reports Offer
  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers market data for 2021, 2022, until 2026
  • Market trends (drivers, opportunities, threats, challenges, investment opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements
Related Reports

Myopia and Presbyopia Treatment Market by Type and Geography – Forecast and Analysis 2022-2026: The myopia and presbyopia treatment market share is expected to increase by USD 7.22 billion from 2021 to 2026.

Ophthalmology Therapeutics Market by Product and Geography – Forecast and Analysis 2021-2025: The ophthalmology therapeutics market size has the potential to grow by USD 12.34 billion during 2020-2025

Open-Angle Glaucoma Therapeutics Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 7.18%

Market growth 2022-2026

USD 2.58 billion

Market structure

Fragmented

YoY growth (%)

5.03

Regional analysis

North America, Europe, APAC, and Rest of World (ROW)

Performing market contribution

North America at 51%

Key consumer countries

US, Canada, Mexico, Japan, UK, and Germany

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

AbbVie Inc., Aerie Pharmaceuticals Inc, Alcon Inc., Bausch Health Co Inc, D.Western Therapeutics Institute Inc, Hikma Pharmaceuticals Plc, Laboratories Sophia, Merck and Co. Inc., Nicox SA, Novartis AG, Ocuphire Pharma Inc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., PharmaMar SA, Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd, Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Market Dynamics

Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse Health Care Market Reports

Table of Contents

1 Executive Summary

  • 1.1 Market overview 
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem 
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition 
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis 
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021-2026 
    • Exhibit 13: Chart on Global – Market size and forecast 2021-2026 ($ million)
    • Exhibit 14: Data Table on Global – Market size and forecast 2021-2026 ($ million)
    • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
    • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

  • 4.1 Five forces summary 
    • Exhibit 17: Five forces analysis – Comparison between 2021 and 2026
  • 4.2 Bargaining power of buyers 
    • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
  • 4.3 Bargaining power of suppliers 
    • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
  • 4.4 Threat of new entrants 
    • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
  • 4.5 Threat of substitutes 
    • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
  • 4.6 Threat of rivalry 
    • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
  • 4.7 Market condition 
    • Exhibit 23: Chart on Market condition – Five forces 2021 and 2026

5 Market Segmentation by Product

  • 5.1 Market segments 
    • Exhibit 24: Chart on Product – Market share 2021-2026 (%)
    • Exhibit 25: Data Table on Product – Market share 2021-2026 (%)
  • 5.2 Comparison by Product 
    • Exhibit 26: Chart on Comparison by Product
    • Exhibit 27: Data Table on Comparison by Product
  • 5.3 PGAs – Market size and forecast 2021-2026 
    • Exhibit 28: Chart on PGAs – Market size and forecast 2021-2026 ($ million)
    • Exhibit 29: Data Table on PGAs – Market size and forecast 2021-2026 ($ million)
    • Exhibit 30: Chart on PGAs – Year-over-year growth 2021-2026 (%)
    • Exhibit 31: Data Table on PGAs – Year-over-year growth 2021-2026 (%)
  • 5.4 Non-PGAs – Market size and forecast 2021-2026
    • Exhibit 32: Chart on Non-PGAs – Market size and forecast 2021-2026 ($ million)
    • Exhibit 33: Data Table on Non-PGAs – Market size and forecast 2021-2026 ($ million)
    • Exhibit 34: Chart on Non-PGAs – Year-over-year growth 2021-2026 (%)
    • Exhibit 35: Data Table on Non-PGAs – Year-over-year growth 2021-2026 (%)
  • 5.5 Market opportunity by Product 
    • Exhibit 36: Market opportunity by Product ($ million)

6 Customer Landscape

  • 6.1 Customer landscape overview 
    • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

  • 7.1 Geographic segmentation 
    • Exhibit 38: Chart on Market share by geography 2021-2026 (%)
    • Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
  • 7.2 Geographic comparison 
    • Exhibit 40: Chart on Geographic comparison
    • Exhibit 41: Data Table on Geographic comparison
  • 7.3 North America – Market size and forecast 2021-2026
    • Exhibit 42: Chart on North America – Market size and forecast 2021-2026 ($ million)
    • Exhibit 43: Data Table on North America – Market size and forecast 2021-2026 ($ million)
    • Exhibit 44: Chart on North America – Year-over-year growth 2021-2026 (%)
    • Exhibit 45: Data Table on North America – Year-over-year growth 2021-2026 (%)
  • 7.4 Europe – Market size and forecast 2021-2026
    • Exhibit 46: Chart on Europe – Market size and forecast 2021-2026 ($ million)
    • Exhibit 47: Data Table on Europe – Market size and forecast 2021-2026 ($ million)
    • Exhibit 48: Chart on Europe – Year-over-year growth 2021-2026 (%)
    • Exhibit 49: Data Table on Europe – Year-over-year growth 2021-2026 (%)
  • 7.5 APAC – Market size and forecast 2021-2026
    • Exhibit 50: Chart on APAC – Market size and forecast 2021-2026 ($ million)
    • Exhibit 51: Data Table on APAC – Market size and forecast 2021-2026 ($ million)
    • Exhibit 52: Chart on APAC – Year-over-year growth 2021-2026 (%)
    • Exhibit 53: Data Table on APAC – Year-over-year growth 2021-2026 (%)
  • 7.6 Rest of World (ROW) – Market size and forecast 2021-2026
    • Exhibit 54: Chart on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
    • Exhibit 55: Data Table on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
    • Exhibit 56: Chart on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
    • Exhibit 57: Data Table on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
  • 7.7 US – Market size and forecast 2021-2026
    • Exhibit 58: Chart on US – Market size and forecast 2021-2026 ($ million)
    • Exhibit 59: Data Table on US – Market size and forecast 2021-2026 ($ million)
    • Exhibit 60: Chart on US – Year-over-year growth 2021-2026 (%)
    • Exhibit 61: Data Table on US – Year-over-year growth 2021-2026 (%)
  • 7.8 Canada – Market size and forecast 2021-2026
    • Exhibit 62: Chart on Canada – Market size and forecast 2021-2026 ($ million)
    • Exhibit 63: Data Table on Canada – Market size and forecast 2021-2026 ($ million)
    • Exhibit 64: Chart on Canada – Year-over-year growth 2021-2026 (%)
    • Exhibit 65: Data Table on Canada – Year-over-year growth 2021-2026 (%)
  • 7.9 Japan – Market size and forecast 2021-2026
    • Exhibit 66: Chart on Japan – Market size and forecast 2021-2026 ($ million)
    • Exhibit 67: Data Table on Japan – Market size and forecast 2021-2026 ($ million)
    • Exhibit 68: Chart on Japan – Year-over-year growth 2021-2026 (%)
    • Exhibit 69: Data Table on Japan – Year-over-year growth 2021-2026 (%)
  • 7.10 UK – Market size and forecast 2021-2026
    • Exhibit 70: Chart on UK – Market size and forecast 2021-2026 ($ million)
    • Exhibit 71: Data Table on UK – Market size and forecast 2021-2026 ($ million)
    • Exhibit 72: Chart on UK – Year-over-year growth 2021-2026 (%)
    • Exhibit 73: Data Table on UK – Year-over-year growth 2021-2026 (%)
  • 7.11 Germany – Market size and forecast 2021-2026
    • Exhibit 74: Chart on Germany – Market size and forecast 2021-2026 ($ million)
    • Exhibit 75: Data Table on Germany – Market size and forecast 2021-2026 ($ million)
    • Exhibit 76: Chart on Germany – Year-over-year growth 2021-2026 (%)
    • Exhibit 77: Data Table on Germany – Year-over-year growth 2021-2026 (%)
  • 7.12 Mexico – Market size and forecast 2021-2026
    • Exhibit 78: Chart on Mexico – Market size and forecast 2021-2026 ($ million)
    • Exhibit 79: Data Table on Mexico – Market size and forecast 2021-2026 ($ million)
    • Exhibit 80: Chart on Mexico – Year-over-year growth 2021-2026 (%)
    • Exhibit 81: Data Table on Mexico – Year-over-year growth 2021-2026 (%)
  • 7.13 Market opportunity by geography 
    • Exhibit 82: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers
  • 8.2 Market challenges
  • 8.3 Impact of drivers and challenges 
    • Exhibit 83: Impact of drivers and challenges in 2021 and 2026
  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview
  • 9.2 Vendor landscape 
    • Exhibit 84: Overview on Criticality of inputs and Factors of differentiation
  • 9.3 Landscape disruption 
    • Exhibit 85: Overview on factors of disruption
  • 9.4 Industry risks 
    • Exhibit 86: Impact of key risks on business

10 Vendor Analysis

  • 10.1 Vendors covered 
    • Exhibit 87: Vendors covered
  • 10.2 Market positioning of vendors 
    • Exhibit 88: Matrix on vendor position and classification
  • 10.3 AbbVie Inc. 
    • Exhibit 89: AbbVie Inc. – Overview
    • Exhibit 90: AbbVie Inc. – Product / Service
    • Exhibit 91: AbbVie Inc. – Key offerings
  • 10.4 Aerie Pharmaceuticals Inc 
    • Exhibit 92: Aerie Pharmaceuticals Inc – Overview
    • Exhibit 93: Aerie Pharmaceuticals Inc – Product / Service
    • Exhibit 94: Aerie Pharmaceuticals Inc – Key offerings
  • 10.5 Alcon Inc. 
    • Exhibit 95: Alcon Inc. – Overview
    • Exhibit 96: Alcon Inc. – Business segments
    • Exhibit 97: Alcon Inc. – Key offerings
    • Exhibit 98: Alcon Inc. – Segment focus
  • 10.6 Bausch Health Co Inc 
    • Exhibit 99: Bausch Health Co Inc – Overview
    • Exhibit 100: Bausch Health Co Inc – Business segments
    • Exhibit 101: Bausch Health Co Inc – Key news
    • Exhibit 102: Bausch Health Co Inc – Key offerings
    • Exhibit 103: Bausch Health Co Inc – Segment focus
  • 10.7 Hikma Pharmaceuticals Plc 
    • Exhibit 104: Hikma Pharmaceuticals Plc – Overview
    • Exhibit 105: Hikma Pharmaceuticals Plc – Business segments
    • Exhibit 106: Hikma Pharmaceuticals Plc – Key offerings
    • Exhibit 107: Hikma Pharmaceuticals Plc – Segment focus
  • 10.8 Nicox SA 
    • Exhibit 108: Nicox SA – Overview
    • Exhibit 109: Nicox SA – Product / Service
    • Exhibit 110: Nicox SA – Key offerings
  • 10.9 Novartis AG 
    • Exhibit 111: Novartis AG – Overview
    • Exhibit 112: Novartis AG – Business segments
    • Exhibit 113: Novartis AG – Key offerings
    • Exhibit 114: Novartis AG – Segment focus
  • 10.10 Otsuka Pharmaceutical Co. Ltd. 
    • Exhibit 115: Otsuka Pharmaceutical Co. Ltd. – Overview
    • Exhibit 116: Otsuka Pharmaceutical Co. Ltd. – Product / Service
    • Exhibit 117: Otsuka Pharmaceutical Co. Ltd. – Key offerings
  • 10.11 Pfizer Inc. 
    • Exhibit 118: Pfizer Inc. – Overview
    • Exhibit 119: Pfizer Inc. – Product / Service
    • Exhibit 120: Pfizer Inc. – Key news
    • Exhibit 121: Pfizer Inc. – Key offerings
  • 10.12 Viatris Inc. 
    • Exhibit 122: Viatris Inc. – Overview
    • Exhibit 123: Viatris Inc. – Business segments
    • Exhibit 124: Viatris Inc. – Key offerings
    • Exhibit 125: Viatris Inc. – Segment focus

11 Appendix

  • 11.1 Scope of the report
  • 11.2 Inclusions and exclusions checklist 
    • Exhibit 126: Inclusions checklist
    • Exhibit 127: Exclusions checklist
  • 11.3 Currency conversion rates for US$ 
    • Exhibit 128: Currency conversion rates for US$
  • 11.4 Research methodology 
    • Exhibit 129: Research methodology
    • Exhibit 130: Validation techniques employed for market sizing
    • Exhibit 131: Information sources
  • 11.5 List of abbreviations 
    • Exhibit 132: List of abbreviations
About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: media@technavio.com

Website: www.technavio.com/



Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/open-angle-glaucoma-therapeutics-market-to-record-a-cagr-of-7-18-development-of-biologics-to-be-a-key-trend—technavio-301633119.html

SOURCE Technavio

rt

Source link

The content is by PR Newswire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy